Literature DB >> 26891023

Nonalcoholic fatty liver disease and elastography: Incremental advances but work still to be done.

William N Hannah1, Stephen A Harrison1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26891023     DOI： 10.1002/hep.28504

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  7 in total

Review 1.  Imaging Modalities in Pediatric NAFLD.

Authors:  Suraj D Serai; Jennifer Panganiban; Manish Dhyani; Andrew J Degnan; Sudha A Anupindi
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

2.  Response to a letter to the editor.

Authors:  Venkatram Krishnan
Journal:  Abdom Radiol (NY)       Date:  2021-02

3.  Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis.

Authors:  Layal Al Danaf; Mohammed Hussein Kamareddine; Emilie Fayad; Aniqa Hussain; Said Farhat
Journal:  World J Hepatol       Date:  2022-04-27

4.  A Pyridazinone Compound for Effectively Treating Non-alcoholic Steatohepatitis by Targeting THRβ.

Authors:  Hao Cheng; Xiao-Bo Wang; Ying Zhi; Bo Liu; Na Liu; Meng-Jun Li; Yan-Ling Mu
Journal:  Front Chem       Date:  2022-05-10       Impact factor: 5.545

5.  Ultraconserved element uc.372 drives hepatic lipid accumulation by suppressing miR-195/miR4668 maturation.

Authors:  Jun Guo; Weiwei Fang; Libo Sun; Yonggang Lu; Lin Dou; Xiuqing Huang; Weiqing Tang; Liqing Yu; Jian Li
Journal:  Nat Commun       Date:  2018-02-09       Impact factor: 14.919

Review 6.  Current status of imaging in nonalcoholic fatty liver disease.

Authors:  Qian Li; Manish Dhyani; Joseph R Grajo; Claude Sirlin; Anthony E Samir
Journal:  World J Hepatol       Date:  2018-08-27

7.  Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).

Authors:  Jessica Min-DeBartolo; Franklin Schlerman; Sandeep Akare; Ju Wang; James McMahon; Yutian Zhan; Jameel Syed; Wen He; Baohong Zhang; Robert V Martinez
Journal:  PLoS One       Date:  2019-12-31       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.